We have just published an editorial by Denis Horgan of the European Alliance for Personalised Medicine (EAPM), which discusses the barriers involved in getting novel drugs and treatments swiftly to where they are really needed.
Factors such as slow bench-to-bedside rates are negatively affecting cancer patients across the EU. Horgan describes how personalised medicine can improve the situation, holding huge potential for improving the health of many patients and ensuring better outcomes for health systems’ efficiency and transparency.
Read the full editorial here.
Watch this video for more on health economics.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.